Outcome from treatment of Pneumocystis jirovecii pneumonia with co-trimoxazole

Int J STD AIDS. 2009 Sep;20(9):652-3. doi: 10.1258/ijsa.2009.008470.

Abstract

A retrospective case-notes audit of 359 HIV-1-infected adult patients with first-episode laboratory-confirmed Pneumocystis jirovecii pneumonia treated with co-trimoxazole (from 1987 adjuvant steroids were used if PaO(2) <9.3 kPa) showed that only 230/359 (64%) patients completed treatment; 104 (29%) patients had treatment-limiting toxicity; rash occurred in 4/60 (6.7%) patients in 1985-1988 and in 15/47 (31.9%) in 2005-2008. Twenty-five patients (7%) failed co-trimoxazole treatment. Overall mortality was 13.6% (49/359); mortality among patients who failed co-trimoxazole treatment was 48% (12/25) and by contrast mortality was 4.8% (5/104) among patients with treatment-limiting toxicity.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Adult
  • Anti-Infective Agents / therapeutic use*
  • Female
  • Humans
  • Male
  • Pneumocystis carinii*
  • Pneumonia, Pneumocystis / drug therapy*
  • Retrospective Studies
  • Treatment Outcome
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*

Substances

  • Anti-Infective Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination